Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis


  • Conflicts of interest

    • Dr. Wu received research grants from Abbott Laboratories, AbbVie, Amgen, and Pfizer, which were not directly related to this study. Dr. Curtis has received grant/research support from Roche/Genentech, UCB, Centocor, Consortium of Rheumatology Researchers of North American (CORRONA), Amgen, Pfizer, Bristol-Myers Squibb, Crescendo, and Abbott; and has been a consultant for Roche/Genentech, UCB, Centocor, CORRONA, Amgen, Pfizer, Bristol-Myers Squibb, Crescendo, and Abbott. Dr. Harrold has a research contract with the CORRONA. In the last 2 years Abbvie, Amgen, AstraZeneca, Janssen, Genentech, Lilly, Novartis, Pfizer, Vertex and UCB have supported CORRONA through contracted subscriptions to the database. Dr. Herrinton has research contracts with Centocor, Genentech, Proctor and Gamble, and Medimmune. Dr. Asgari has research contracts with Genentech, Valeant, and Pfizer and received grant funding to Kaiser Permanente institution from Pfizer, Genentech and Valeant Pharmaceuticals.. The other co-authors do not have any disclosures.
  • Funding sources

    • The National Institute for Allergy and Infectious Diseases, National Institutes of Health (1RC1AI086107) did not participate in authoring this work.



Psoriasis may predispose to cardiovascular disease and diabetes. However, the role of tumor necrosis factor (TNF) inhibitor in mediating this risk is controversial.


To assess this relationship, we estimated change in metabolic physiologic measures before and after initiation of TNF inhibitor therapy compared with methotrexate (MTX) therapy among psoriasis patients.


We conducted a retrospective cohort study, 2007–2012, using computerized clinical data for 1274 new users of TNF inhibitor and 979 new users of MTX therapy to compare change in blood pressure, lipids, triglycerides, fasting plasma glucose and body mass index (BMI) before and after start of TNF inhibitors or MTX. The study was restricted to new users. We computed within-person change in each measure, so that each patient served as their own control. In addition, we compared TNF inhibitor patients to MTX patients, by computing the adjusted difference in their group means. In secondary analyses, we examined phototherapy as a comparator.


Among starters of TNF inhibitor and MTX therapy, within-person change in physiologic measures at 6 months did not differ significantly. We observed no important or significant changes in any of the physiologic measures with initiation of TNF inhibitor compared with MTX. The same results were found in subgroup analyses focused on men, and on those with hypertension, diabetes mellitus, or obesity. The same results were observed with phototherapy, except that diastolic blood pressure declined by 0.6 mmHg within person during the 6 months after starting phototherapy (< 0.05).


The study provides no evidence for improvement of physiologic measures associated with the metabolic syndrome resulting from TNF inhibitor use for psoriasis.